文献速递淋巴瘤

套细胞淋巴瘤中环状RNA的表达模式与预后潜力:MCL2和MCL3临床试验年轻患者研究

Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
PubMed 文献 · Leukemia · 2021-07-09

本研究利用RNA测序描绘套细胞淋巴瘤(MCL)的环状RNA(circRNA)表达图谱,并在北欧MCL2和MCL3临床试验样本中用NanoString nCounter技术探索40种高丰度circRNA的预后价值。在MCL2训练队列中构建的circSCORE可高度预测进展时间(TTP)和淋巴瘤特异性生存(LSS),并在MCL3独立验证队列中证实高风险组预后差(TTP HR 3.0,P=0.0004;LSS HR 3.6,P=0.001)。多因素Cox回归纳入MIPI、Ki67指数、母细胞形态和TP53突变后,circSCORE对TTP(HR 3.2,P=0.01)和LSS(HR 4.6,P=0.01)仍保持预后意义。

要点

  • circSCORE在MCL2训练队列中预测TTP和LSS,并在MCL3独立队列中验证。
  • 高风险组TTP的HR为3.0(P=0.0004),LSS的HR为3.6(P=0.001)。
  • 调整MIPI、Ki67、母细胞形态和TP53突变后,circSCORE仍独立预后。

核心结论

  • circRNA是有前景的MCL预后生物标志物,circSCORE可改善接受含阿糖胞苷化学免疫治疗和自体干细胞移植的年轻高危患者的识别。

研究设计与样本

  • 利用RNA测序描绘circRNA表达图谱,并用NanoString nCounter技术在北欧MCL2和MCL3临床试验样本中探索40种高丰度circRNA的预后潜力。

主要发现

  • 在MCL2训练队列中构建的circSCORE可高度预测TTP和LSS。
  • 在MCL3独立验证队列中,circSCORE高风险组TTP的HR为3.0(P=0.0004),LSS的HR为3.6(P=0.001)。

关键数值与推荐

  • 多因素Cox回归纳入MIPI、Ki67指数、母细胞形态和TP53突变后,circSCORE对TTP的HR为3.2(P=0.01),对LSS的HR为4.6(P=0.01)。

临床怎么用

  • circSCORE可能有助于在年轻MCL患者中识别高风险个体,这些患者接受含阿糖胞苷化学免疫治疗和自体干细胞移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is characterized by marked differences in outcome, emphasizing the need for strong prognostic biomarkers. Here, we explore expression patterns and prognostic relevance of circular RNAs (circRNAs), a group of endogenous non-coding RNA molecules, in MCL. We profiled the circRNA expression landscape using RNA-sequencing and explored the prognostic potential of 40 abundant circRNAs in samples from the Nordic MCL2 and MCL3 clinical trials, using NanoString nCounter Technology. We report a circRNA-based signature (circSCORE) developed in the training cohort MCL2 that is highly predictive of time to progression (TTP) and lymphoma-specific survival (LSS). The dismal outcome observed in the large proportion of patients assigned to the circSCORE high-risk group was confirmed in the independent validation cohort MCL3, both in terms of TTP (HR 3.0; P = 0.0004) and LSS (HR 3.6; P = 0.001). In Cox multiple regression analysis incorporating MIPI, Ki67 index, blastoid morphology and presence of TP53 mutations, circSCORE retained prognostic significance for TTP (HR 3.2; P = 0.01) and LSS (HR 4.6; P = 0.01). In conclusion, circRNAs are promising prognostic biomarkers in MCL and circSCORE improves identification of high-risk disease among younger patients treated with cytarabine-containing chemoimmunotherapy and autologous stem cell transplant.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Dahl M, Husby S, Eskelund CW, et al. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. Leukemia. 2021. PMID: 34244612. doi:10.1038/s41375-021-01311-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。